Reporter brief
Systematic review: GLP-1 agonists associated with reduced mortality and epigenetic aging markers in clinical trials.
What happened
This systematic review synthesizes evidence on GLP-1 receptor agonists as potential geroprotective agents. Clinical trials showed: SELECT trial found 19% reduction in all-cause mortality (HR 0.81) in obese patients without diabetes; FLOW trial showed 24% reduction in primary kidney composite endpoint (HR 0.76); and a 2025 semaglutide trial demonstrated significant deceleration of three DNA methylation aging clocks (DunedinPACE, PCGrimAge, PhenoAge) over 32 weeks. Mechanistic evidence links benefits to hypothalamic GLP-1 receptor signaling, AMPK/SIRT1 pathways, and microbiome-derived short-chain fatty acids.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Systematic review; Human.
Patients with obesity, with and without diabetes; diverse age groups
- Design
- Systematic review
- Sample
- —
- Journal
- Experimental gerontology
- Published
- Sep 14, 2026
Effect size
SELECT trial: 19% reduction in all-cause mortality (HR 0.81); FLOW trial: 24% reduction in primary kidney composite endpoint (HR 0.76); 32 weeks of semaglutide: significant deceleration of DunedinPACE, PCGrimAge, and PhenoAge
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.